ArticleScience China. Life sciences2026
Berberine combined with stachyose protects against obesity by modulating gut microbiota and increasing leptin sensitivity.
Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bile acids as a "new hormone" in aging-related liver disease.Life medicine · 2026Review
- Alnustone ameliorates obesity and polycystic ovary syndrome by remodeling adipose metabolism via AMPK signaling.Science China. Life sciences · 2026Article
- Probiotics-derived postbiotics improve host metabolic syndrome by activating the adipocyte thermogenic signaling pathway in high-fat diet-fed mice.iMetaOmics · 2026Article
- Berberine: A Negentropic Modulator for Multi-System Coordination.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptin resistance is a hallmark of obesity. Recent evidence shows that gut microbiota is associated with the development and progression of leptin resistance. However, whether intervention targeting gut microbiota can improve leptin sensitivity remains to be fully established. In the current investigation, we have demonstrated that co-administration of berberine, an isoquinoline alkaloid compound, and stachyose, a prebiotic, could enhance leptin sensitivity and reduce body weight in diet-induced obesity (DIO) mice, via an effect associated with gut microbiota modulation. Notably, the combination of berberine and stachyose significantly increased the abundance of Blautia producta, altered host purine metabolism, and elevated serum and hypothalamic levels of a purine metabolite, inosine. Furthermore, direct supplementation with inosine further ameliorated inflammation and endoplasmic reticulum stress in the hypothalamus and improved leptin sensitivity in obese mice. These findings suggest that berberine combined with stachyose represents a novel leptin sensitizer for obesity, acting through the modulation of gut microbiota and subsequently alteration in host purine metabolism, particularly with the involvement of inosine.
Indexed as
Identifiers
41077606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.